The Compliance Committee functions pursuant to a written charter adopted by the Board, a copy of which may be found at our website www.neogenomics.com under the heading 'Investors - Governance - Governance Documents.' All committee members are independent directors within the meaning of the applicable Nasdaq rules. The Compliance Committee is responsible for overseeing the Company's activities in the area of compliance with applicable laws and regulations related to our provision of medical-related services and assessing management's implementation of the Company's Corporate Compliance Program elements, including but not limited to the: - adequacy and effectiveness of policies and procedures to ensure the Company's compliance with applicable laws and regulations and all associated risk, - organization, responsibilities, plans, results, budget, staffing, and performance of the Company's Compliance Department, including its independence, authority and reporting obligations, - reviewing and concurring in the appointment, replacement, reassignment, or dismissal of the Chief Compliance Officer and review of significant reports to management or summaries thereof regarding the Company's compliance policies, practices, procedures and programs, and management's responses thereto, - monitoring of significant internal and external investigations of the Company's business, - monitoring of the Company's implementation of actions in response to applicable legislative, regulatory, and legal developments, - Company's Code of Conduct and written compliance policies and procedures that guide the Company and the conduct of its staff, - appropriate mechanisms for employees to seek guidance to report concerns, and - Company's systems and processes designed to periodically assess the Company's compliance obligation and associated risks and efforts to promote an ethical culture.